




Shanghai LIDE Biotech, Co. Ltd.

Lab for Innovated Diagnosis and Experimental Therapeutics

**PDX / CDX / Cell Line Lists /
Rare Drug Resistant & Genetically Modified PDX Models**

Q1-2022

Structured to Bring “Bench to Bedside” to Life



1600+ PDX Models Available:



Cancer	No.	Cancer	No.	Cancer	No.
Pancreatic	299	Sarcoma	26	AML	13
Gastric	193	Cervical	16	ALL	9
Ovarian	186	Endometrial	15	MM	3
Lung	145	Duodenum	14	Neuroendocrine	4
Colon	102	Lymphoma	14	Bladder	4
Hepatocellular	96	HNC	6	Malignant pleural mesothel	2
Cholangiocarcinoma	78	Renal	7	Penile	2
Rectal	69	Mucinous carcinoma	5	Fallopian tube carcinoma	2
Glioblastoma	68	Prostate	7	Paget's Disease	1
Osteosarcoma	42	GIST	6	SCPF	1
Breast	41	ACC	5	Spleen	1
Esophageal	41	Urethral	3	MGST	1
Gallbladder	35	Periampullary	2	Chordoma	1
Hepatoblastoma	36	Melanoma	2		

Cancer	Cell line
Liver	HepG2,Hep-3B,Huh7,SNU-398
Colon	Lovo,HT-29,Colo205,SW480,HCT-116,SW620
Breast	MDA-MB-231,MDA-MB-468,HCC1954
Gastric	MKN-45,NCI-N87,SNU-16, KATOIII, BGC823
Pancreatic	MIA-Paca-2
Prostate	PC-3,LNCap,Du 145
Kidney	A498
Melanoma	A375
Epidermoid carcinoma	A431
Leukemia	K562, Jurkat
Fibrosarcoma/Rhabdomyosarcoma	HT-1080

Cancer	Cell line
Glioblastoma	U87MG
Esophageal	KYSE30
Cervical	Hela
Multiple Myeloma	MOLP-8
Melanoma	SK-MEL-5
Lung	A549,H460,H2009,H1975,H1703,HCC827,H2122,NCI-H226,Calu-3,H1299
Lymphoma	Raji,Daudi,NALM-6
Ovarian	SK-OV-3,OVCAR-3,A2780,PA-1

LIDE Biobank: 100+ human cancer cell lines



Cancer	Cell line
Colon	Lovo, HT-29, Colo205, SW48, SW480, SW837, HCT-116, SW620, GP2D, RKO, SK-CO-1, DLD1, Colo 741
Breast	MDA-MB-231, MDA-MB-468, HCC-1954, BT474, MDA-MB-157, MDA-MB-453, SK-BR-3, T-47D, MCF7
Gastric	MKN-45, NCI-N87, SNU-16, KATO III, KATO3-T5-BN, BGC823, SNU-5, NUGC4, MKN28, Hep3B, Hs746T
Prostate	PC-3, LNCap, Du 145, 22RV1
Melanoma	A375, SK-MEL-5
Liver	HepG2, Hep-3B, Huh7, SNU-398, SK-HEP-1
Lymphoma	Raji, Daudi, NALM-6, KARPAS-299, MV4-11, OCI-LY3
Leukemia/MM	K562, Jurkat
Fibrosarcoma	HT-1080
Epidermoid carcinoma	A431

Cancer	Cell line
Ovarian	SK-OV-3, OVCAR-3, A2780, PA-1, ES-2, EFO-21, TOV-21G
Pancreatic	MIA-Paca-2, Aspc-1, BXPC-3, HPAC, PANC-05.04, PANC-1, SW1990, Panc10.05, Capan 2
Lung	A549, CALU-1, H460, DMS14, H2009, H1975, H1703, HCC827, H2122, NCI-H226, Calu-3, H1299, H23, H358, SK-LU-1, EBC-1, H1993, H596, NCI-H441
Osteosarcoma	143B, MG-63, Saos-2, U-2 OS
Esophageal	KYSE30, OE19
Glioblastoma	U87MG, U251, A172, LN-229, U-118 MG
AML	MOLM-13, OCI-AML2
Bladder Cancer	5637
Kidney	A498
Cervical	Hela

LIDE Biobank: Popular Target Expression Human Cancer Cell Lines



Expression/mutation	Cell line	Cancer
Claudin18.2 high expression	OE19	Esophageal cancer
	NUGC4	Gastric cancer
	KATO III	Gastric cancer
TROP2 high expression	A172	Glioblastoma
	LN-229	Brain medulloblastoma
	U-87 MG	Brain astroblastoma
	MKN28	Gastric cancer
ERBB3 high expression	MKN45	Gastric cancer
	Hep G2	Liver cancer
	MCF7	Breast cancer
GPC3 high expression	Hep G2	Liver cancer
	Hep3B	Liver cancer
	Huh-7	Liver cancer
GPC3 no expression	SK-HEP-1	Liver cancer
MET amplification	EBC-1	Lung squamous
	Hs746T	Gastric cancer
	H1993	NSCLC
MET exon 14 skipping	H596	Lung squamous
KRAS G12D	Panc-1	Pancreatic cancer
	GP2D	Colon cancer
	SK-LU-1	Lung adenocarcinoma
	Aspc-1	Metastatic pancreatic
	SW1990	Pancreatic cancer
	panc10.05	Pancreatic cancer


Expression/mutation	Cell line	Cancer
LRRC15 high expression	U-87 MG	Brain astroblastoma
	U-118 MG	Astroblastoma
	143B	Osteosarcoma
	MG-63	Osteosarcoma
	Saos-2	Osteosarcoma
HER2 high expression	OE19	Esophageal cancer
	SK-BR-3	Breast cancer
KRAS G12C	MIA PACA-2	Pancreatic cancer
KRAS G13D	DLD1	Colon cancer
KRAS G61H	NCI-H460	Lung cancer
KRAS G12V	NCI-H441	Pancreatic cancer
	Capan 2	Pancreatic cancer
	PANC 03.27	Pancreatic cancer
	SW620	Colon cancer
BRAF V600E	HT29	Colon cancer
	Colo 205	Colon cancer
	Colo 741	Rectal cancer
CDH6 high expression	143B	Osteosarcoma
	U-2 OS	Osteosarcoma
	EFO-21	Ovarian cancer
	NCI-N87	Gastric cancer
FRα high expression	SK-OV-3	Ovarian cancer
	TOV-21G	Ovarian cancer
GPR20	EFO-21	Ovarian cancer

Cancer Type	Resistant To:	Rare Specific Genetic Alteration(s)	
NSCLC	Eriotinib Osimertinib Crizotinib Brigatinib Anti PD-L1 ab	EGFR: exon19del/T790M/L858R/exon20ins/C797S ALK: EML4-ALK/L1196M Cmet: ampli/exon14ski/CD47-MET RET: KIF5B-RET	ROS1: CD74-ROS1/G2032R KRAS: G12C PTEN: Y68X P13K: E726K
Breast Cancer	CDK4/6i	TNBC/ER+	
Multiple Myeloma	Bortezomib	CD47+/CD38+	
Cholangiocarcinoma	Paclitaxel	KRAS: G12C	FGFR: BICC1-FGFR2
Colorectal Cancer	Avastin	KRAS: G12C	BRAF: V600E
Hematological Malignancy	Rituximab Imatinib	/	
Gastric Cancer	Herceptin	HER2: ampli	KRAS: G12C
Brain Cancer	/	EGFR: VIII	cMET: PTPRZ1-MET
Melanoma	Anti PD-1 ab	BRAF: V600E	
Ovarian Cancer	Platinum PARPi	/	

Application of the Highest Industry Standards




International Lab and Research Standards



Setting PDX Standards in China

LIDE-lead PDX Consortium



Chinese Government Issued Certifications

